[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:circulating-tumor-derived-dna-negative":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Circulating Tumor-Derived DNA Negative",32,29,[8,16,22,28,34,40,47,53,59,65,71,76,82,88,94,101,107,113,118,125,131,137,143,149,155,161,167,173,178,184,191,198],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07023289","A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease",[12],"Phase 2","RECRUITING","2026-08-26T02:16:32.589113Z","2026-07-05T05:32:16.725869Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06923527","Circulating Tumor DNA",[12],"2026-08-26T02:15:26.669629Z","2026-07-05T05:32:16.704259Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07136077","A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy",[12],"2026-08-03T01:00:21.999836Z","2026-07-05T05:32:16.660205Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06617858","Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment",[12],"2026-08-26T02:17:45.190188Z","2026-05-13T02:55:06.563134Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT06005818","Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)",[12],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:29.372544Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":45,"content_modified":46},"NCT03803553","Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",[44],"Phase 3","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.200175Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06517212","Tirzepatide Weight Loss for MRD+ Early Breast Cancer",[12],"2026-08-26T02:19:11.399072Z","2026-05-05T02:43:28.970389Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05715229","Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy",[12],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.654619Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT06083844","Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy",[12],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.496123Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT07183319","Circulating Tumor DNA Response In Urothelial Cancer",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:28.470064Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":69,"content_modified":75},"NCT07227636","A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy",[12],"2026-05-05T02:43:28.364702Z",{"nct_id":77,"title":78,"phases":79,"status":13,"updated_at":80,"content_modified":81},"NCT06364917","DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC",[12],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:28.192654Z",{"nct_id":83,"title":84,"phases":85,"status":13,"updated_at":86,"content_modified":87},"NCT04434040","Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)",[12],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.827881Z",{"nct_id":89,"title":90,"phases":91,"status":13,"updated_at":92,"content_modified":93},"NCT07096362","Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma",[12],"2026-08-26T02:18:47.742071Z","2026-05-05T02:43:27.622110Z",{"nct_id":95,"title":96,"phases":97,"status":13,"updated_at":99,"content_modified":100},"NCT04920032","Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas",[98],"Phase 1","2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.053498Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT07191717","Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:26.896756Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":111,"content_modified":112},"NCT06358430","Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)",[98],"2026-08-03T03:29:04.388436Z","2026-05-05T02:43:26.768422Z",{"nct_id":114,"title":115,"phases":116,"status":13,"updated_at":14,"content_modified":117},"NCT05343013","TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy",[12],"2026-05-05T02:35:31.745839Z",{"nct_id":119,"title":120,"phases":121,"status":13,"updated_at":123,"content_modified":124},"NCT07504796","ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",[122],"Phase 4","2026-08-26T02:18:40.612983Z","2026-04-29T02:57:57.166829Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT06828991","A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP",[12],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.283059Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT07282912","Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels",[12],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:28.285786Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":141,"content_modified":142},"NCT05482516","Evaluating Novel Therapies in ctDNA Positive GI Cancers",[44],"2026-08-26T02:18:55.570428Z","2026-04-29T02:57:57.077131Z",{"nct_id":144,"title":145,"phases":146,"status":13,"updated_at":147,"content_modified":148},"NCT07726602","Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual\u002FRecurrent Disease - the TiMBER Trial",[],"2026-08-26T02:15:23.202838Z","2026-07-30T01:46:14.447290Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT05653388","Metastatic Leiomyosarcoma Biomarker Protocol",[],"2026-08-26T02:17:19.710918Z","2026-07-05T05:32:16.806328Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT04616131","Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy",[],"2026-08-26T02:17:03.534765Z","2026-06-18T12:24:03.101835Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT07332975","ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC",[],"2026-08-26T02:18:15.214990Z","2026-05-13T02:55:06.695288Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT06966050","Multi-center MRD Registry for Inflammatory Breast Cancer",[],"2026-08-26T02:18:56.409949Z","2026-05-13T02:55:06.602265Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":51,"content_modified":177},"NCT06878131","Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease",[],"2026-05-13T02:55:06.589009Z",{"nct_id":179,"title":180,"phases":181,"status":13,"updated_at":182,"content_modified":183},"NCT07058012","A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)",[12],"2026-08-26T02:19:07.104270Z","2026-07-05T05:32:16.733669Z",{"nct_id":185,"title":186,"phases":187,"status":188,"updated_at":189,"content_modified":190},"NCT07698535","Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial",[12],"NOT_YET_RECRUITING","2026-08-26T02:17:16.980188Z","2026-07-19T19:36:05.080439Z",{"nct_id":192,"title":193,"phases":194,"status":195,"updated_at":196,"content_modified":197},"NCT04567420","DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:34:16.012157Z","2026-05-05T02:43:28.129432Z",{"nct_id":199,"title":200,"phases":201,"status":195,"updated_at":203,"content_modified":204},"NCT04093167","Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer",[202],"Phase 2\u002FPhase 3","2026-08-03T03:43:00.111924Z","2026-05-05T02:35:31.754382Z"]